Genmab — Februar 2019
-
Har gennem lang tid suppleret i niveau 1000. Men kan alligevel ikke få mig selv til at sælge lidt. Synes hele tiden der lige er en nyhed der venter
-
Jeg har købt lidt ekstra Genmab aktier
i den seneste tid for momspengene i nogle af familiens firmaer. Skal bruge pengene fredag og måtte derfor sælge ud i går og i dag.
-
Det er ellers nogle år siden jeg har ladet mig friste af den slags drengestreger.
-
Ses vi?
Økonomisk Ugebrev Biotech har nu fornøjelsen at invitere til årets første Investorkonference – Onsdag d. 6. marts i København: https://ugebrev.dk/begivenheder/biotech-investorkonference-q1-2019/
-
Bemærk: Gratis adgang.
-
-
Lige en til fe søvnige: Goldmann Sachs cheføkonom siger at det tyder på at verdensøkonomien har bundet for denne gang ! Det peger op! Øh - stakkels alle dem der gik og ventede på en nedtur. Bussen kørte måske forbi dem
-
nice ranking by Institutional Investor https://twitter.com/RachelGravesen/status/1100844183143809024 , and I honestly have to say, well deserved, they have improved soo much over the last few years
-
Så fortjent.
-
Af hjertet tak for donation: http://www.proinvestor.com/network
-
-
Rachel Gravesen @RachelGravesen
Unlikely that daratumumab SC formulation will be submitted under RTOR as that program is only for sBLAs and the SC version will need to be a full BLA as it is a new formulation.
09:33 - 28 feb. 2019 vanuit Princeton Junction, NJ https://twitter.com/RachelGravesen/status/1101037575605764096
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind